Home / Stocks / Rubicon Research Limited
RUBICON

Rubicon Research Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹1,722.3

Change

+64.0 (3.86%)

Open

₹1,658.3

Prev. Close

₹1,658.3

Day High

₹1,745.1

Day Low

₹1,650.8

Volume Analysis

Traded

152,518

Delivered

87,779

Delivery %

57.55%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Strong return on equity (27.0%)
  • •Strong operating margin (24.0%)

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (2)

  • •Strong 3-year revenue growth (64.5%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,855.64 ₹1,800.37 ₹1,761.34 ₹1,706.07 ₹1,667.04 ₹1,611.77 ₹1,572.74
Fibonacci ₹1,800.37 ₹1,764.35 ₹1,742.09 ₹1,706.07 ₹1,670.05 ₹1,647.79 ₹1,611.77
Camarilla ₹1,748.23 ₹1,739.59 ₹1,730.94 ₹1,706.07 ₹1,713.66 ₹1,705.01 ₹1,696.37

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+154.59%

1 Week

+0.29%

1 Month

+18.9%

3 Months

-0.14%

6 Months

+81.34%

1 Year

+147.4%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹169.69

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

19.32%

Net margin 15.48% × asset turnover 0.64x × equity multiplier 1.95x

Company Overview

Sector

Healthcare

Market Cap

₹27,764 Cr

P/E (TTM)

85.5

ROE

27.0%

Book Value

₹85.6

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 14 Nov 2026. Not investment advice.

TopFund Analysis

Rubicon Research Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 70/100. The strongest factor is Growth (100/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (27.0%); strong operating margin (24.0%); promoter holding is falling. Strong 3-year revenue growth (64.5%).

TopFund Score — Fundamentals Quality

70/100 — Good

Data confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

97

Growth

100

Valuation

0

Cash Flow

21

Corporate Governance

60

Momentum

83

Institutional Ownership

68

Business Quality

94

Risk & Volatility

82

Liquidity

57

From Screener.in

  • +Company is expected to give good quarter
  • +Company has delivered good profit growth of 52.0% CAGR over last 5 years
  • +Company has a good return on equity (ROE) track record: 3 Years ROE 27.5%
  • −Stock is trading at 19.6 times its book value
  • −Promoter holding has decreased over last quarter: -8.51%
  • −Working capital days have increased from 68.8 days to 104 days

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Transcript of Earnings Call -Q2 - FY 2026-27

Newspaper Publication for Q2 ended September 30, 2026 Financial Results

Audio recording of Q2 and half-year FY2026 earnings call available on website.

Revised Q2 FY26 IPO monitoring report shows Rs. 4,329.07 million utilized; no deviation from objects.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 296 313 358 352 412 476 514 534 576
Expenses + 234 244 286 273 318 367 395 405 432
Operating Profit 62 70 72 79 94 108 119 129 144
OPM % 21.0% 22.0% 20.0% 22.0% 23.0% 23.0% 23.0% 24.0% 25.0%
Other Income + 3 0 0 1 1 4 3 6 2
Interest 7 8 12 11 11 10 10 9 11
Depreciation 8 9 10 10 12 12 12 15 18
Profit before tax 49 53 51 60 72 91 99 110 117
Tax % 30.0% 28.0% 29.0% 27.0% 25.0% 20.0% 22.0% 23.0% 23.0%
Net Profit + 34 38 36 43 54 73 77 85 90
EPS in Rs 2 3 2 3 3 4 5 5 5
Raw PDF — — — — — — — — —
YoY Sales growth — — — — 39 52 43 52 40

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 263 315 314 394 854 1,284 1,754 2,100
Expenses + 182 223 353 375 699 1,020 1,354 1,600
Operating Profit 81 92 -39 18 155 264 400 500
OPM % 31.0% 29.0% -12.0% 4.7% 18.0% 21.0% 23.0% 24.0%
Other Income + 18 10 17 25 18 4 8 14
Interest 6 9 10 19 31 37 42 41
Depreciation 18 29 34 36 39 37 45 57
Profit before tax 74 63 -66 -11 103 195 321 417
Tax % 33.0% 51.0% 2.0% 53.0% 12.0% 31.0% 23.0% —
Net Profit + 49 31 -67 -17 91 134 247 325
EPS in Rs 3 2 -4 -1 6 9 15 20
Dividend Payout % 2.0% 2.0% 0.0% -2.0% 0.0% 0.0% 10.0% —
Sales growth — 20 0 26 117 50 37 46

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 335 369 300 281 370 526 1,272 1,400
Borrowings + 30 93 175 320 425 418 311 501
Other Liabilities + 60 71 79 144 300 493 727 843
Total Liabilities 430 538 560 750 1,109 1,451 2,327 2,761
Fixed Assets + 157 188 193 199 307 327 532 803
CWIP 2 6 3 25 10 7 41 90
Investments 19 14 0 0 0 0 27 29
Other Assets + 252 330 364 526 793 1,118 1,728 1,839
Total Assets 430 538 560 750 1,109 1,451 2,327 2,761
Equity Capital 5 5 5 5 15 15 17 17

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 5 62 -63 -75 21 159 205
Cash from Investing Activity + -84 -46 -46 -32 -68 -65 -407
Cash from Financing Activity + 80 52 63 123 44 -40 283
Net Cash Flow 1 67 -45 16 -4 54 81
Free Cash Flow -54 -10 -117 -119 -35 91 -24
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 40 104 138 -394 25 75 78

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 59.99% → 51.25%
  Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 22.57% 22.57% 23.29% 24.03%
Promoters 59.99% 59.86% 59.76% 51.25%
FII 7.99% 7.54% 7.52% 9.01%
DII 9.45% 10.02% 9.43% 15.73%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Rubicon Research Limited (this stock) 27,764 85.5 19.59 27.0%
Neuland Lab Ltd. 27,106 59.9 13.35 21.2%
Krishna Inst Of Med Sci L 31,903 157.0 8.11 11.3%
Acutaas Chemicals Limited 32,281 73.5 17.37 24.0%
Piramal Pharma Limited 32,557 — 4.0 -3.83%
Wockhardt Limited 32,944 82.4 6.39 6.11%
Granules India Limited 22,226 31.7 3.39 13.8%

Which Mutual Funds Hold Rubicon Research Limited?

Frequently Asked Questions about Rubicon Research Limited

Community Sentiment

What are other investors saying about Rubicon Research Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.